Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | NQO2 | P16083 | 2/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.36 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30259222 | 1.00 | ALDH1A1 (0.46) | ALDH1A1CYP3A4TDP1MAPK1TAAR1 | |
| SCHEMBL116606 | 0.82 | ALDH1A1 (0.69) | ALDH1A1CYP3A4TDP1MAPK1NQO2 | |
| SCHEMBL5800828 | 0.82 | ALDH1A1 (0.59) | ALDH1A1CYP3A4TDP1MAPK1NQO2 | |
| SCHEMBL168353 | 0.82 | ALDH1A1 (0.69) | ALDH1A1CYP3A4TAAR1NQO2CYP19A1 | |
| SCHEMBL186502 | 0.82 | ALDH1A1 (0.59) | ALDH1A1CYP3A4TAAR1NQO2CYP1A1 | |
| SCHEMBL8999877 | 0.80 | MEN1 (0.43) | ALDH1A1CYP3A4TDP1SMN1; SMN2MEN1 | |
| Ammonia Solution, Strong SCHEMBL10988442 | 0.79 | ALDH1A1 (0.65) | ALDH1A1CYP3A4TDP1MAPK1NQO2 | |
| SCHEMBL30365875 | 0.79 | ALDH1A1 (0.65) | ALDH1A1CYP3A4TDP1MAPK1NQO2 | |
| SCHEMBL21611343 | 0.79 | ALDH1A1 (0.65) | ALDH1A1CYP3A4TDP1MAPK1NQO2 | |
| Hydrochloric Acid SCHEMBL3275940 | 0.79 | ALDH1A1 (0.65) | ALDH1A1CYP3A4TDP1MAPK1NQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 235 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118290306-B | Nitrogen mustard derivative and preparation method thereof | 西南科技大学 | 2025-03-04 | — | — | CN | claimed |
| CN-118290306-A | Novel nitrogen mustard derivative and preparation method thereof | 西南科技大学 | 2024-07-05 | — | — | CN | claimed |
| US-12545654-B2 | MYC inhibitors and uses thereof | STEMSYNERGY THERAPEUTICS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| EP-4673149-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | Trustlife Global Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| US-12486253-B2 | Therapeutics for the degradation of mutant BRAF | C4 THERAPEUTICS, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| EP-4624471-A1 | PKMYT1 INHIBITOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) | 2025-10-01 | — | — | EP | disclosed |
| US-12384778-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2025-08-12 | — | — | US | disclosed |
| US-12338226-B2 | Substituted benzodiazoles and use thereof in therapy | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2025-06-24 | — | — | US | disclosed |
| US-12331057-B2 | Modulators of alpha-1 antitrypsin | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-17 | — | — | US | disclosed |
| US-20250171399-A1 | PYRROLIDINE COMPOUNDS | ELI LILLY AND COMPANY | 2025-05-29 | — | — | US | disclosed |
| CN-119954828-A | Parallel ring compound and preparation and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2025-05-09 | — | — | CN | disclosed |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-26 | — | — | US | disclosed |
| WO-2008061781-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | NV REMYND (BE) | 2008-05-29 | — | — | WO | disclosed |
| US-7320989-B2 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2008-01-22 | — | — | US | disclosed |
| US-7320989-B2 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2008-01-22 | — | — | US | disclosed |
| US-7320989-B2 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2008-01-22 | — | — | US | disclosed |
| US-20080004312-A1 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS, INC. | 2008-01-03 | — | — | US | disclosed |
| US-20080004312-A1 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS, INC. | 2008-01-03 | — | — | US | disclosed |
| US-20080004312-A1 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS, INC. | 2008-01-03 | — | — | US | disclosed |
| US-20050054850-A1 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS INC. | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384778-B2 | Pyrazolopyridine compounds and uses thereof | PDXK, PCK1, PGK1 | ALDH1A1 2205/4885CYP3A4 1456/4885TDP1 506/4885 |
| US-12486253-B2 | Therapeutics for the degradation of mutant BRAF | BRAF, NRAS, KRAS | ALDH1A1 1471/4885CYP3A4 4325/4885TDP1 726/4885 |
| US-20050054850-A1 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | UTS2R, GPR17, NTSR2 | ALDH1A1 3771/4885CYP3A4 2407/4885TDP1 3331/4885 |
| US-20250171399-A1 | PYRROLIDINE COMPOUNDS | SDHA, GMPS, SDHB | ALDH1A1 978/4885CYP3A4 23/4885TDP1 1870/4885 |
| US-12331057-B2 | Modulators of alpha-1 antitrypsin | SERPINA2, SERPINC1, SERPINA3 | ALDH1A1 477/4885CYP3A4 1833/4885TDP1 560/4885 |
| US-20080004312-A1 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | UTS2R, GPR17, NTSR2 | ALDH1A1 3771/4885CYP3A4 2407/4885TDP1 3331/4885 |
| US-12545654-B2 | MYC inhibitors and uses thereof | MYC, MYCBP, NR2E1 | ALDH1A1 4317/4885CYP3A4 4008/4885TDP1 2366/4885 |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | ALDH1A1 1930/4885CYP3A4 3900/4885TDP1 47/4885 |
| US-12338226-B2 | Substituted benzodiazoles and use thereof in therapy | XDH, CYP11B2, CYP4X1 | ALDH1A1 274/4885CYP3A4 10/4885TDP1 1726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.